Serum proteomic profiling at diagnosis predicts clinical course, and need for intensification of treatment in inflammatory bowel disease.

ABSTRACT:

Background

Success in personalized medicine in complex disease is critically dependent on biomarker discovery. We profiled serum proteins using a novel proximity extension assay [PEA] to identify diagnostic and prognostic biomarkers in inflammatory bowel disease [IBD].

Methods

We conducted a prospective case-control study in an inception cohort of 552 patients [328 IBD, 224 non-IBD], profiling proteins recruited across six centres. Treatment escalation was characterized by the need for biological agents or surgery after initial disease remission. Nested leave-one-out cross-validation was used to examine the performance of diagnostic and prognostic proteins.

Results

A total of 66 serum proteins differentiated IBD from symptomatic non-IBD controls, including matrix meta

SUBMITTER: Kalla R 

PROVIDER: S-EPMC8095384 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature